As shown in Figure 4, panel 2, for subjects with a known poor CYP2D6 metabolizer status, median steady‐state concentrations after dosing of 300‐mg AOM (as recommended)12 remained centered within the therapeutic window, while concentrations following dosing of 400‐mg AOM approached the upper limit of the therapeutic window. Here, CYP2D6 is linked to infectious otitis media.